PT  - JOURNAL ARTICLE
AU  - Berenstein, A.J.
AU  - Falk, N.
AU  - Moscatelli, G.
AU  - Moroni, S.
AU  - González, N.
AU  - Garcia-Bournissen, F.
AU  - Ballering, G.
AU  - Freilij, H.
AU  - Altcheh, J.
TI  - Adverse events associated with nifurtimox treatment for Chagas disease in children and adults
AID  - 10.1101/2020.06.02.20118000
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.02.20118000
4099  - http://medrxiv.org/content/early/2020/06/05/2020.06.02.20118000.short
4100  - http://medrxiv.org/content/early/2020/06/05/2020.06.02.20118000.full
AB  - BACKGROUND Nifurtimox (NF) is one of the only two drugs currently available for Chagas disease (ChD) treatment. However, there is scarce data on NF safety, and many physicians defer or refuse NF treatment because of concerns about drug tolerance.METHODS Prospective cohort study with retrospective data collection of adverse drug reactions (ADRs) associated with NF treatment of ChD. Children received NF doses of 10-15 mg/kg/day for 60-90 days, and adults 8-10 mg/kg/day for 30 days.RESULTS 215 children (median age: 2.6yrs, range 0-17) and 105 adults (median age: 34yrs, range 18-57) were enrolled. Overall, 127/320 (39.7%) patients developed ADRs, with an incidence of 64/105 in adults, and 63/215 in children (OR = 3.7, 95%CI [2.2;6.3]). We observed 215 ADRs, 131 in adults (median: 2 events/patient (IQR25-75= 1-3) and 84 in children (median: 1 event/patient (IQR25-75= 1-1.5) (Wilcoxon-Test, PAdjusted < 8.10-5). ADRs were mainly mild and moderate. Severe ADRs were infrequent (1.2% in children and 0.9% in adults). Nutritional, central nervous and digestive systems were the most frequently affected, without differences between both groups.Treatment was discontinued in 31/320 (9.7%) patients without differences between groups. However, ADR-related discontinuations occurred more frequently in adults than in children (OR = 5.5, 95%CI = [1.5;24]).CONCLUSIONS Our study supports the safety of NF for ChD treatment. Delaying NF treatment due to safety concerns does not seem to be supported by the evidence.Competing Interest StatementJA is a consultant of Bayer. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of InterestClinical TrialNCT04274101Funding StatementThis work was supported by an Institution initiative research by Bayer [grant number PR5071885]. A.J.B., F.G.B., G.M. and J.A, are researchers in the National Scientific and Technical Research Council of Argentina (CONICET).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study protocol was approved by the research and teaching committee and the bioethics committee of the Children Hospital Ricardo Gutierrez, Buenos Aires.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable